Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical leader advancing novel psychedelic-based therapies for mental health conditions. This dedicated news hub provides investors and researchers with essential updates on the company's progress in developing innovative treatment solutions.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships that shape Cybin's research pipeline. Our curated collection includes official press releases detailing advancements in deuterated compound research, intellectual property achievements, and collaborative neuroscience initiatives.
Key updates cover FDA designations, preclinical study results, and patent filings that demonstrate Cybin's scientific rigor in psychedelic therapeutics development. The resource serves as a centralized tracking point for material events influencing the company's position in mental health innovation.
Bookmark this page for structured access to verified information about Cybin's therapeutic candidates and operational developments. Check regularly for objective updates on progress within the regulated biopharmaceutical research landscape.
Cybin has submitted an Investigational New Drug (IND) application to the FDA for its CYB003, a deuterated psilocybin analog, aiming to treat major depressive disorder (MDD). This milestone follows successful IND-enabling work, with expectations to initiate Phase 1/2a clinical trials in mid-2022. The trial is a randomized, double-blind, placebo-controlled study that will assess the rapid onset of antidepressant effects and safety. Preliminary pharmacokinetic and safety data are expected by year-end 2022.
Cybin Inc. will participate in the morning trading bell ceremony at the New York Stock Exchange on
Cybin Inc. (NYSE American: CYBN) has announced that CEO Doug Drysdale will participate in a fireside chat during the H.C. Wainwright Global Investment Hybrid Conference from May 23-26, 2022, at Fontainebleau Miami Beach. The live webcast of the chat is scheduled for May 25, 2022, at 12:30 p.m. ET. Interested listeners can access the event through the company's investor relations website.
Cybin focuses on developing psychedelics into therapeutics, working with a network of partners to create effective treatments for mental health challenges.
Cybin Inc. and Kernel announce positive pilot results from a feasibility study utilizing Kernel's Flow technology to assess neuro-effects of ketamine. Conducted over 11 days, the study confirmed changes in functional connectivity consistent with existing research. Results will be presented at the PSYCH Symposium in London on May 11, 2022. This study, which received FDA Investigational New Drug authorization, paves the way for advancements in psychedelic therapeutics, highlighting the potential of real-time brain activity measurement.
Cybin announced that its deuterated psilocybin analog, CYB003, will be presented at the 'From Research to Reality' Global Summit on Psychedelic-Assisted Therapies, scheduled for May 27-29, 2022, in Toronto. The abstract, titled Pharmacological and Pharmacokinetic Profile of CYB003, indicates that CYB003 may offer therapeutic benefits over traditional psilocybin, including improved dosing accuracy and tolerability. Cybin aims to advance treatment options for mental health disorders through its innovative drug development strategies.
Cybin, a biopharmaceutical company, will have CEO Doug Drysdale presenting at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022, at 11:00 a.m. ET. This live online event allows investors to interact and ask questions directly. Cybin focuses on developing therapeutics using psychedelics to address mental health issues through innovative drug discovery platforms and treatment regimens. Investors can register for the event via the provided link and access the archived webcast later.
Cybin Inc. has partnered with Clinilabs Drug Development Corporation to conduct a Phase 1/2a clinical trial for CYB003, a proprietary deuterated psilocybin analog, aimed at treating major depressive disorder (MDD). This marks the first evaluation of a psilocybin analog in clinical trials for MDD. The partnership is expected to expedite the regulatory pathway for CYB003, which has shown advantages in preclinical studies, including better tolerability and faster action compared to classic psilocybin. An IND filing with the FDA is anticipated in Q2 2022.
Cybin Inc. announced promising preclinical results for its proprietary drug CYB004, delivered via inhalation. The study indicates that inhaled CYB004 has a rapid onset, longer action duration, and over 40% improved bioavailability compared to inhaled DMT. These findings may position inhalation as a viable method for delivering therapeutic psychedelics. Cybin aims to address the limitations associated with IV administration of DMT in treating anxiety disorders. The company plans to file for a pilot study by Q2 2022 and commence it in Q3 2022.
Cybin Inc. (AMEX:CYBN) has announced the publication of an international patent application by the World Intellectual Property Organization (WIPO) covering inhalation delivery methods for various psychedelic molecules. This PCT application strengthens Cybin’s intellectual property position, particularly for its CYB004 pipeline program utilizing deuterated DMT via inhalation. The patent allows the company to pursue applications for multiple inhaled forms of psychedelics, aligning with its strategy of creating improved treatment options for mental health disorders.
Cybin announces participation in the Benzinga Psychedelics Capital Conference on April 19, 2022. CEO Doug Drysdale will engage in a fireside chat at 1:10 p.m. ET and a panel discussion at 3:10 p.m. ET focused on catalysts in the psychedelics industry. The event will be streamed live, and recordings will be available on the company’s investor relations website. Founded in 2019, Cybin is a biopharmaceutical firm dedicated to creating effective therapeutics for mental health issues, operating in multiple countries including Canada and the U.S.